Kariya Pharmaceuticals ApS: Financial statements 2018
CVR: 39270684
Source: annual report 2018, Danish Business Authority
18/01/2018 – 31/12/2018
Kariya Pharmaceuticals ApS (CVR 39270684) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 0 and a net result of DKK 0. Equity in the 2018 report amounted to DKK 100. The solvency ratio was 100%.
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 0
- Equity
- DKK 100
- Total Assets
- DKK 100
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of November 28, 2018, Ian Rodney Laquian has stepped down as adm. dir. of Kariya Pharmaceuticals ApS.
As of January 18, 2018, Ian Rodney Laquian is registered as adm. dir. of Kariya Pharmaceuticals ApS.
Kariya Pharmaceuticals ApS was founded on January 18, 2018.
About Kariya Pharmaceuticals ApS
Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.